Soonsolid Completes ￥100M Series B Financing, Focusing on the R&D of Digital Products in Dentistry

According to PEdaily.cn, Zhejiang Xunshi Technology Co., Ltd. (Soonsolid) announced that it has closed Series B Financing of more than 100 million yuan with participation from CD Capital and Marathon Venture Partners. Proceeds from this financing will be used to develop digital products in dentistry and expand the market.

Founded in 2013, Soonsolid is a high-tech enterprise specialized in the R&D, manufacturing, sales, and service of the 3D printing industry, which is located in Keqiao district, Shaoxing city, Zhejiang province and co-founded by selected talents of the "thousand talents plan" of Zhejiang province and domestic high-level talents.

Soonsolid has a research team, composed of a number of domestic and foreign doctors (professors) who have rich technical reserves in the field of digital rapid prototyping.

Soonsolid not only maintains close communication and cooperation with many domestic universities and scientific research institutions for a long time, but also has established a cooperative relationship with the world-renowned rapid prototyping laboratory of the university of southern California in the United States to carry out the most cutting-edge 3D printing technology docking and cooperation, and has obtained advanced research results of 3D printing technology. 

Soonsolid provides advanced DLP Industrialization with Stereo Lithography Appearance (SLA) system solutions. Its products include a variety of self-developed DLP SLA equipment and 3D printing consumables, covering consumer, industrial and medical sectors. The company masters the 3D printing, SIS consumer metal printing, and other technologies. 

CD Capital is a venture capital firm specialized in life sciences and medical technology. They are currently managing both RMB and USD funds with a total size of $600M. CD Capital is operated by a professional team with diversified and profound industry backgrounds. 

CD Capital has made over 40 investments with high growth potential and earned a reputation as a premier venture capital firm with the main focus on the healthcare industry in China. With a broad network around China and the world, they have been able to seize the global trend, capture investment opportunities as well as help to define the future for China healthcare industry. Ultimately, they strive to grow best-in-class companies and deliver solid financial returns to their investors.

Marathon Venture Partners is an international VC fund that focuses on early and growth-stage companies in the healthcare and Fintech industry, with offices in Beijing, Shanghai, Suzhou, and Hong Kong. Marathon currently manages both US Dollar and RMB funds.

Marathon has invested in 38 companies. The MVP partners collectively have 40+ years investment and operating experience, and have a proven track record of identifying and scaling future industry champions.